FDA Approves Blueprint Medicines Ayvakit (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis

FDA Approves Blueprint Medicines Ayvakit (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis

First precision therapy that specifically targets the primary driver of the disease Durable clinical...
read more